UnknownNot Applicable

Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF)

Panama40 participantsStarted 2017-05-19

Plain-language summary

A feasibility study to investigate the safety and performance of the NeuroTronik Cardiac Autonomic Nerve Stimulation (CANS) Therapy System

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Systolic Blood Pressure \< 90 mmHg or \> 160 mmHg
✕. Catecholamine or inotropic therapy within the previous 48 hours
✕. Levosimendan within the previous 72 hours
✕. Chronic outpatient catecholamine or inotropic therapy
✕. Presence of implanted pacemaker, implantable cardioverter defibrillator or cardiac resynchronization therapy device
✕. Presence of or prior vagal nerve stimulator
✕. Coronary artery bypass graft surgery, percutaneous coronary intervention, acute myocardial infarction, or valve replacement within prior 1 month
✕. Second or third degree heart block

Arterial blood pressure

Timeframe: 24 hours

Heart Rate

Timeframe: 24 hours

NCT IDNCT03169803

SponsorNeuroTronik Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2019-05-19

Temístocles Díaz, MD